Ultragenyx Pharmaceutical Investors Urged to Act Before Securities Class Action Deadline

Important Announcement for Ultragenyx Investors

As the deadline approaches for filing a securities class action against Ultragenyx Pharmaceutical Inc (NASDAQ: RARE), affected investors are urged to take action. Faruqi & Faruqi, LLP, a prominent national securities law firm, is leading the charge in seeking justice for shareholders who have experienced losses related to the company's stock performance. Investors who acquired shares between August 3, 2023, and December 26, 2025, need to be aware of this legal opportunity.

Context of the Investigation

Ultragenyx has recently come under scrutiny for its alleged failure to disclose crucial information regarding the effectiveness of its Osteogenesis Imperfecta (OI) treatment, setrusumab. Reports indicate that the company created a misleading narrative regarding the safety and effectiveness of their treatments, particularly concerning the Phase III Orbit study outcomes. The lawsuit claims that investors were misled about the reliability of the data and were not informed of the risks that led to the study's disappointing results.

Timeline of Events

The situation escalated when on July 9, 2025, Ultragenyx disclosed that the Phase III Orbit study didn't meet statistical significance during its second interim analysis. Consequently, this disclosure triggered a steep 25% drop in their stock price, impacting many investors nearly overnight. Further compounding these issues, a subsequent announcement on December 29, 2025, indicated that the company’s efforts in the Phase III Orbit and Cosmic Studies were also unsuccessful in achieving the intended statistical significance against primary endpoints. Following this news, the stock plunged over 42%, leading to increased distress among shareholders.

Role of Lead Plaintiff

The class action lawsuit is designed to provide a pathway for investors to recoup some of their losses. A lead plaintiff is typically appointed in these cases, representing the interests of all affected investors. This individual will collaborate with the legal team to guide the case forward. Any member of the affected class may assert their right to serve as lead plaintiff or simply remain part of the class without taking any active role. Investors are reminded that their potential recovery is not influenced by their choice to serve as lead plaintiff.

Open Call for Whistleblowers

Faruqi & Faruqi also invites anyone with relevant information about Ultragenyx's practices—past employees, shareholders, or whistleblowers—to step forward. This additional testimony could provide more insight into the company's alleged wrongdoing and strengthen the case.

Conclusion

In light of this unfolding situation, investors should remain vigilant and consider their options regarding potential claims against Ultragenyx Pharmaceutical. The deadline to seek lead plaintiff status in the class action is set for April 6, 2026. Those interested in learning more about their legal rights or participating in this action are encouraged to reach out directly to the firm via the provided contact information. Keeping abreast of such developments can mitigate losses and foster a sense of accountability among corporate entities.

For more information on this matter, or if you wish to engage in the legal proceedings, please visit Faruqi & Faruqi's website or contact James (Josh) Wilson at 877-247-4292.